RxDoctor Payments DataLook up a doctor →

Robert Brown, MD

Urology · Richmond, VANPI 1609830165

Payments from drug & device makers

$16,495in general payments, 2019–2025

Across 770 payments — averaging $21.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dendreon Pharmaceuticals LLC$2K
  • Bayer$1K
  • Johnson & Johnson$1K
  • Astellas Pharma US Inc$1K
  • AbbVie$1K
  • Sumitomo Pharma America, Inc.$1K
  • plus $9K from 48 others

What the payments were for

  • Consulting fees$5403%
  • Food & beverage$15,86796%
  • Education$881%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,495 in reported general payments places this provider in the 80th percentile of 300 urology providers in Virginia.

See all urology providers in Virginia

Medicare billing

Part B allowed, 2024
$344,512
Medicare patients
1,199
Services billed
14,672

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron242$216,534
GemtesaVibegron43$39,202
Mirabegron ErMirabegron36$30,533
OrgovyxRelugolix11$29,289
Tadalafil68$16,890
Tolterodine Tartrate148$16,455
Finasteride871$10,926
Tamsulosin Hcl808$10,238
Estradiol135$8,481
Tolterodine Tartrate ErTolterodine Tartrate66$6,990
CefuroximeCefuroxime Axetil384$5,959
Silodosin29$3,295
Solifenacin Succinate36$2,954
Testosterone15$2,708
Potassium Citrate ErPotassium Citrate12$1,060

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$1,162$216,534242 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$1,031$68,49154 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 300 urology providers in Virginia.

Other urology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →